{"key":"op_800_CN","page":{"url":"https://us-uk.bookimed.com/clinics/country=china/procedure=car-t-cell-therapy/","procedure":{"id":800,"slug":"car-t-cell-therapy","name":"CAR T-cell therapy","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"hematology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":203,"iso":"CN","name":"China"},"currency":"USD","data_date":"2026-10-29"},"pages":{"clinics_url":"https://us-uk.bookimed.com/clinics/country=china/procedure=car-t-cell-therapy/","cost_url":"https://us-uk.bookimed.com/clinics/country=china/procedure=car-t-cell-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":275000,"to":319000,"avg":{"value":275000,"method":"median","source":"clinics"},"us":{"from":420000,"to":540000},"uk":{"from":330000,"to":420000},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Shanghai","from":275000},{"city":"Qionghai","from":319000},{"city":"Beijing","from":185000},{"city":"Guangzhou","from":185000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":90000,"to":150000},{"country_iso":"FR","from":295000,"to":385000},{"country_iso":"GB","from":330000,"to":420000},{"country_iso":"US","from":420000,"to":540000},{"country_iso":"IL","from":84000,"to":405000},{"country_iso":"TR","from":150000,"to":220000},{"country_iso":"MX","from":120000,"to":185000},{"country_iso":"DE","from":285000,"to":365000},{"country_iso":"CA","from":340000,"to":470000},{"country_iso":"AE","from":190000,"to":310000},{"country_iso":"TH","from":150000,"to":220000},{"country_iso":"PL","from":165000,"to":230000},{"country_iso":"KR","from":220000,"to":300000},{"country_iso":"CZ","from":150000,"to":195000},{"country_iso":"AT","from":280000,"to":365000},{"country_iso":"ES","from":380000,"to":520000},{"country_iso":"IT","from":400000,"to":650000},{"country_iso":"AU","from":330000,"to":420000},{"country_iso":"IN","from":38000,"to":70000},{"country_iso":"MY","from":120000,"to":180000},{"country_iso":"VN","from":150000,"to":230000},{"country_iso":"BR","from":280000,"to":400000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":35,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":5,"items":[{"id":6749,"name":"Lu Daopei Hematology Hospital","city":"Beijing","rating":3,"reviews_count":1,"accreditations":{"status":"missing","reason":"not_collected"},"rank":1,"has_procedure":true,"why_ranked":"2,782 patients enrolled in CAR-T trials. 27 studies presented at EBMT. Multiple CAR-T programs: CD7-directed, myeloma, with radiotherapy. Hematologist with 900+ treatments.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":7869,"name":"Shanghai Tongji Hospital, International Department","city":"Shanghai","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":2,"has_procedure":true,"why_ranked":"87.5% complete remission at 3 months for lymphoma. 1,500+ CAR-T infusions performed since 2014. Multidisciplinary tumor board manages each case.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":7994,"name":"Boao International Medical Center","city":"Qionghai","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":436,"name":"Fuda Cancer Hospital","city":"Guangzhou","rating":4.6,"reviews_count":19,"accreditations":{"status":"missing","reason":"not_collected"},"rank":4,"has_procedure":true,"why_ranked":"JCI-accredited cancer hospital in Guangzhou with 30,000+ patients from 100 countries. Its CAR T-cell program is led by the hospital president, a clinical oncologist.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":8327,"name":"Uni-asia Cancer hospital","city":"Chengdu","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":5,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":7,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":2015,"slug":"shanghai","name":"Shanghai","clinics_count":1,"price_from":275000,"profile":{"city_type":"Most populous city in China","access":["Pudong Airport (PVG), 30 km from the city center","Hongqiao Airport (SHA), 13 km from downtown"],"sources":["https://en.wikipedia.org/wiki/Shanghai","https://en.wikipedia.org/wiki/Shanghai_Pudong_International_Airport","https://en.wikipedia.org/wiki/Shanghai_Hongqiao_International_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":2715,"slug":"qionghai","name":"Qionghai","clinics_count":1,"price_from":319000,"profile":{"city_type":"County-level city in Hainan, China","access":["Qionghai Boao Airport (BAR), 12 km from downtown"],"sources":["https://en.wikipedia.org/wiki/Qionghai","https://www.travelchinaguide.com/cityguides/hainan/qionghai-boao-airport.htm"],"checked_at":"2026-11-03","status":"ok"}},{"id":360,"slug":"beijing","name":"Beijing","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":185000,"profile":{"city_type":"Capital city of China","access":["Beijing Capital Airport (PEK), 32 km from downtown"],"sources":["https://en.wikipedia.org/wiki/Beijing","https://en.wikipedia.org/wiki/Beijing_Capital_International_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":390,"slug":"guangzhou","name":"Guangzhou","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":185000,"profile":{"city_type":"Capital of Guangdong, southern China","access":["Guangzhou Baiyun Airport (CAN), 28 km north of downtown"],"sources":["https://en.wikipedia.org/wiki/Guangzhou","https://en.wikipedia.org/wiki/Guangzhou_Baiyun_International_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":2,"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":[{"id":"6a61d811cab311a9ce0552c2","clinic_id":7869,"clinic_listed":true,"price":230000,"price_before_discount":250000,"nights":28,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Parking"],"excluded":["Accommodation is not included","Transfer is not included"],"other_services":"This package only include the medicine of CAR-T therapy (Yikeda® Axicabtagene Ciloleucel Injection).","is_package":true}],"packages":{"status":"missing","reason":"no_offers"},"related_packages":[{"id":"6a61d811cab311a9ce0552c2","clinic_id":7869,"clinic_listed":true,"price":230000,"price_before_discount":250000,"nights":28,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Parking"],"excluded":["Accommodation is not included","Transfer is not included"],"other_services":"This package only include the medicine of CAR-T therapy (Yikeda® Axicabtagene Ciloleucel Injection).","is_package":true,"operation_id":1700,"operation_name":"CAR-T for Multiple Myeloma"},{"id":"6a61da6b251bc5abcf09c632","clinic_id":7869,"clinic_listed":true,"price":350000,"nights":30,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Coffee Zone","24-hr nurse services","Parking","Full board (breakfast+lunch+dinner+drinks)","Hospitalization + afterward hotel stay","VIP transfer (premium vehicle service, all transfers between airport, hotel and clinic)"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Treatment Process Flow Phase 1: Pre-treatment Waiting Period Receive patient inquiry and develop a treatment plan; confirm the patient's travel to China for treatment. Contact the patient to book flight tickets. Phase 2: Pre-treatment Conditioning Stage Airport pickup and hospital admission. Registration and appointment scheduling. Doctor evaluation and consultation; order examinations (MRI, PET-CT, and other comprehensive tests); conduct multidisciplinary consultation (MDT). Blood draw and laboratory testing (apheresis and sample preparation). Laboratory issues reports; doctor interprets the results. Doctor formulates an anti-tumor treatment plan to condition the patient's body to meet the requirements for CAR-T therapy. Patient returns to their home country to wait. CAR-T drug cost (Yikeda® Axicabtagene Ciloleucel Injection). Phase 3: Core Treatment Stage Assistance with medical visa processing. Book flight tickets for the treatment visit to the hospital. Airport pickup and hospitalization at the main hospital. Doctor consultation and re-evaluation before treatment. Preparatory (Lymphodepletion) treatment. Initiation of actual CAR-T treatment. Evaluate treatment efficacy and formulate a discharge plan. Discharge from the hospital and establish a follow-up plan. Book return flight tickets and provide private car transfer. Phase 4: Follow-up Stage Book flight tickets based on the follow-up schedule. Private car pickup for hospital follow-up visits; monthly follow-up examinations for three consecutive months. Blood draw and report interpretation. Organize documents and complete medical records. Patient returns to their home country. Additional Services Included： Professional medical interpretation (English and other languages) at every stage Dedicated bilingual care coordinator Airport transfer & daily transport between hotel and hospital Diet during hospitalization (personal dietary preferences, religious beliefs, and other relevant information will be needed) Hotel reservation assistance Flight booking support Medical visa invitation letter & application guidance Coordination with your home‑country physician and structured post‑discharge follow‑up","is_package":true,"operation_id":1700,"operation_name":"CAR-T for Multiple Myeloma"}],"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"hospital_nights":{"value":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"source":"parsed_details"},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"horizon":"Best response, typically assessed at 1-3 months after infusion","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"missing","reason":"not_collected"},"prep_in_advance":{"status":"missing","reason":"not_collected"},"visit_and_day":{"status":"missing","reason":"not_collected"},"if_something_changes":{"status":"missing","reason":"not_collected"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"days_in_clinic":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","revision_rate_pct":null,"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"unit":"percent","horizon":"Best response, typically assessed at 1-3 months after infusion","evidence_status":"limited","population":"Adults with relapsed/refractory LBCL after two or more prior lines"},"techniques":[{"name":"Autologous CD19-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"name":"Autologous BCMA-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","recovery":"Similar monitoring; prolonged cytopenias are common."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"initial_assessment_documents":["Pathology report with CD19 or BCMA status","Summary of prior treatment lines and responses","Recent PET-CT or MRI report","Bone marrow biopsy report","Recent CBC, kidney and liver function tests","Echocardiogram report (if available)"],"travel_trips":{"min":1,"max":2,"one_trip_possible":true,"qualifier":"Cell collection, then 3-9 weeks manufacturing, usually at home; return for infusion and 4+ weeks nearby. One trip means staying."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":null,"prep_in_advance":null,"visit_and_day":null,"if_something_changes":null}},"techniques":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Similar monitoring; prolonged cytopenias are common."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"British citizens can enter China without a visa for up to 30 days for business, tourism, family or friend visits, or transit, for a limited period","source":{"url":"https://www.gov.uk/foreign-travel-advice/china/entry-requirements","host":"gov.uk","quote":"Until 31 December 2026, you can enter China visa free for stays of up to 30 days for business, tourism, family or friend visits or transit.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US citizens must obtain a visa before arriving in China","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/China.html","host":"travel.state.gov","quote":"You must obtain a visa prior to arriving in the People’s Republic of China (PRC).","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 6 months after arrival in China and have 2 blank pages for visas and stamping","source":{"url":"https://www.gov.uk/foreign-travel-advice/china/entry-requirements","host":"gov.uk","quote":"To enter China, your passport must have an ‘expiry date’ at least 6 months after the date you arrive and 2 blank pages for visas and stamping.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A US passport must have at least six months of validity remaining to enter China","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/China.html","host":"travel.state.gov","quote":"Your passport must have at least six months' validity remaining.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"us","volatile":false,"text":"Carry prescription medication for China in its original packaging, along with the prescription","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/China.html","host":"travel.state.gov","quote":"Carry prescription medication in original packaging, along with the prescription.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"hospital_payment","audience":"all","volatile":false,"text":"Hospitals in China often require payment in cash or by mobile payment app before treatment, including emergency cases","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/China.html","host":"travel.state.gov","quote":"Payment in cash or via mobile payment app for services is often required prior to treatment, including emergency cases.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V7","item":"emergency_number","audience":"all","volatile":false,"text":"Call 120 and ask for an ambulance in China","source":{"url":"https://www.gov.uk/foreign-travel-advice/china/health","host":"gov.uk","quote":"Call 120 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","germany","israel","italy","lithuania","republic-of-korea","spain","thailand","turkey","united-kingdom","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.52,"count":20,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>CAR T-cell therapy in China typically costs from _op_800_price_from_ to _op_800_price_to_. Prices depend on the specific cell product used, clinical protocol, and length of hospital stay. In the United States, similar procedures cost around _price_compare_US_average_ on average. Patients save around _price_percent_discount_% compared to US costs. Standard Chinese packages usually include T-cell collection, laboratory manufacturing, lymphodepletion chemotherapy, and 30 days of specialized inpatient monitoring.</p>\n\n<ul>\n<li><strong>Approved commercial therapies:</strong> _op_800_price_from_ to _op_800_price_to_ for NMPA-cleared products like Axi-cel or Relma-cel.</li>\n<li><strong>Clinical trial pathways:</strong> Often range from 15% to 40% of the cost of commercial drugs.</li>\n<li><strong>Administrative hubs:</strong> Specialized treatment centers are primarily located in Beijing, Shanghai, and Guangzhou.</li>\n<li><strong>Inpatient monitoring:</strong> Typically covers a 4-week stay to manage cytokine release syndrome or neurotoxicity.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> China represents a unique value for refractory blood cancers due to high treatment volumes. Beijing GoBroad Boren Hospital, a top hematology specialist, offers packages starting around $100,000. This includes a full 30-day hospital stay and comprehensive diagnostics. Facilities like Fuda Cancer Hospital hold JCI accreditation, ensuring international safety standards. For complex pediatric cases, centers like Beijing Kyoto Children's Hospital provide specialized wards for high-risk management.</p>","faq":[{"q":"What are the clinical success rates of CAR T-cell therapy in Chinese hospitals?","a":"<p>Chinese hospitals report competitive CAR T-cell therapy success rates, with overall response rates between 79% and 98% for blood cancers. Specialized centers in Beijing and Guangzhou lead in treating relapsed malignancies, often achieving remission rates exceeding 90% for pediatric leukemia and nearly 99% for multiple myeloma.</p> <ul> <li><strong>Blood cancer success:</strong> Overall response rates for B-cell malignancies typically range from 79% to 89%.</li> <li><strong>Multiple myeloma outcomes:</strong> Domestically developed BCMA-targeted therapies show complete remission rates reaching 88.4%.</li> <li><strong>Pediatric leukemia rates:</strong> Specialized wards report remission rates over 90% for relapsed B-cell acute lymphoblastic leukemia.</li> <li><strong>Solid tumor progress:</strong> Emerging trials for gastrointestinal cancers show a 73% disease control rate using CT041.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> China’s FasTCAR technology significantly impacts success by slashing cell manufacturing time to 24–36 hours. This rapidly prevents T-cell exhaustion, which is a common failure point in Western protocols. Clinics like Beijing GoBroad Boren Hospital leverage this speed to treat high-risk patients who cannot wait weeks for infusions.</p> <p><strong>Patient Consensus:</strong> Patients often see impressive immediate remission but emphasize that these figures reflect initial response rather than a guaranteed cure. Maintaining close proximity to intensive care units during the first 2 weeks is vital for managing safe recovery.</p>"},{"q":"Which CAR T-cell products are commercially approved in China?","a":"<p>China has commercially approved 6 CAR T-cell therapy products for treating hematological malignancies. These therapies target CD19 or BCMA proteins to treat relapsed or refractory lymphoma, leukemia, and multiple myeloma. The National Medical Products Administration (NMPA) regulates these approvals for adult and pediatric populations.</p> <ul> <li><strong>CD19-targeted products:</strong> Yescarta (Axi-cel), Carteyva (Relma-cel), and Yorwida (Inaticabtagene autoleucel) treat B-cell lymphomas.</li> <li><strong>Multiple myeloma therapies:</strong> Fucaso (Equ-cel), Zevor-cel, and Carvykti (Cilta-cel) target BCMA for refractory cases.</li> <li><strong>Approval milestones:</strong> Yescarta was the first commercial approval in 2021, followed by domestically developed Carteyva.</li> <li><strong>Recent additions:</strong> Zevor-cel and Carvykti received NMPA approval in 2024 for advanced multiple myeloma.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While commercial approvals suggest broad availability, clinic data shows treatment accessibility is highly concentrated. Facilities like Lu Daopei Hematology Hospital manage massive volumes—200,000 patients annually—because they possess the infrastructure to handle specific commercial products. Patients should note that a 30-day hospitalization is often standard in Chinese protocols to monitor for cytokine release syndrome.</p> <p><strong>Patient Consensus:</strong> Patients often find that commercial availability in China moved faster than in Western countries. However, they emphasize verifying the brand and indication directly with major cancer centers before traveling.</p>"},{"q":"Is China developing CAR T-cell therapies for solid tumors?","a":"<p>China is actively leading the global development of CAR T-cell therapies for solid tumors. While Western nations focus on blood cancers, Chinese biotech firms and oncology centers have scaled hundreds of clinical trials targeting gastric, pancreatic, and liver malignancies using breakthroughs like Satri-cel and Claudin18.2 targeting.</p> <ul> <li><strong>Targeted breakthroughs:</strong> Satri-cel (CT041) is the first regulatory NDA submission for solid tumor CAR-T.</li> <li><strong>Specific biomarkers:</strong> Trials concentrate on Glypican-3 (GPC3) and Claudin18.2 prevalent in gastrointestinal cancers.</li> <li><strong>Agile regulations:</strong> Dual-track Investigator-Initiated Trial (IIT) frameworks fast-track therapies to late-stage patients.</li> <li><strong>Advanced manufacturing:</strong> Closed-loop automation platforms reduce cell production timelines to 24–36 hours.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While large centers like Lu Daopei Hematology Hospital manage 200,000 patients annually, solid tumor CAR-T remains largely investigational. You should prioritize clinics like JCI-accredited Fuda Cancer Hospital. They often combine cellular therapies with minimally invasive techniques like NanoKnife to help penetrate dense tumor masses.</p> <p><strong>Patient Consensus:</strong> Patients value the speed of Chinese innovation but warn that many breakthroughs are small-scale trials. You must verify if a therapy is in an active clinical trial phase.</p>"},{"q":"How long does the CAR T-cell treatment process take in China?","a":"<p>The CAR T-cell treatment process in China typically takes 4 to 8 weeks for the clinical phases. International patients should plan for 1 to 3 months to include pre-assessments and final follow-ups within JCI-accredited facilities like Lu Daopei Hematology Hospital or Fuda Cancer Hospital.</p> <ul> <li><strong>Pre-treatment assessment:</strong> Medical evaluations and tumor typing take 1 to 2 weeks for eligibility.</li> <li><strong>Cell manufacturing:</strong> Advanced proprietary platforms like FasTCAR reduce engineering time to 24–36 hours.</li> <li><strong>Conditioning phase:</strong> A 3-day chemotherapy regimen prepares the body for successful cell infusion.</li> <li><strong>Inpatient monitoring:</strong> Patients stay in specialized wards for 14 to 30 days post-infusion.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While standard manufacturing takes weeks, China's massive hematology centers like Lu Daopei Hospital manage 200,000 patients annually. This high volume allows clinics to offer specialized packages, like those at Beijing GoBroad Boren Hospital, which include 30 full days of hospitalization. This extended stay ensures immediate management of potential side effects like CRS or neurotoxicity during the most critical recovery window.</p> <p><strong>Patient Consensus:</strong> Patients report that while cell collection is quick, manufacturing waits and post-infusion monitoring are the longest phases. Having a bridging therapy plan ready is vital if the disease progresses during the production stage.</p>"}],"h2":[{"text":"How it works","kind":"content"},{"text":"How Much Does CAR T-cell therapy Cost in China?","kind":"content"},{"text":"Discover the Best CAR T-cell therapy Clinics in China: 5 Verified Options and Prices","kind":"content"},{"text":"CAR T-cell therapy Overview in China","kind":"content"},{"text":"Our Trusted Doctors","kind":"ui"},{"text":"Reviews about Bookimed: Discover Patients' Insights","kind":"ui"},{"text":"Related Articles","kind":"ui"},{"text":"Share this content","kind":"ui"},{"text":"Video Stories from Bookimed Patients","kind":"ui"},{"text":"FAQ about CAR T-cell therapy in China","kind":"content"},{"text":"Get a free consultation","kind":"ui"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}